216661-87-9

Basic information

• Product Name: 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE
• Synonyms: 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE;4-(4-Pyridinyl)-1H-pyrazol-3-amine;4-(Pyridin-4-yl)-1H-pyrazol-3-amine;4-(pyridin-4-yl)-1H-pyrazol-5-amine
• CAS NO: 216661-87-9
• Molecular Formula: C₈H₈N₄
• Molecular Weight: 160.18
• Mol File: 216661-87-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 413.8°Cat760mmHg
• Flash Point: 233.3°C
• Appearance: /
• Density: 1.315g/cm³
• Vapor Pressure: 4.68E-07mmHg at 25°C
• Refractive Index: 1.673
• PKA: 12.82±0.50(Predicted)
• CAS DataBase Reference: 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE(216661-87-9)
• EPA Substance Registry System: 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE(216661-87-9)

Safety Data

• Hazardous Substances Data: 216661-87-9(Hazardous Substances Data)

Usage

Description

4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE, also known as 4-(4-Pyridinyl)-1H-pyrazol-3-amine, is an organic compound that serves as a key reactant in the synthesis of various pharmaceutical products. It is characterized by its unique molecular structure, which features a pyridine ring and a pyrazole ring connected through an amine group. 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE plays a crucial role in the development of new drugs and therapeutic agents.

Uses

Used in Pharmaceutical Industry:
4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE is used as a reactant for the synthesis of various pharmaceutical products. Its unique molecular structure allows it to form stable complexes with other molecules, making it a valuable component in the development of new drugs and therapeutic agents.
4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE is used as a building block for the creation of novel drug candidates. Its ability to form stable complexes with other molecules enables the design of drugs with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE is also used in the development of prodrugs. Prodrugs are biologically inactive compounds that are converted into active drugs within the body. The use of 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE in prodrug design can improve the pharmacokinetic properties of the final drug, such as absorption, distribution, metabolism, and excretion.
Furthermore, 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE can be used in the synthesis of drug conjugates. Drug conjugates are hybrid molecules that combine the therapeutic effects of two or more different drugs. The use of 4-PYRIDIN-4-YL-2H-PYRAZOL-3-YLAMINE in drug conjugate synthesis can lead to the development of multi-targeted therapies, which can be more effective in treating complex diseases.

InChI:InChI=1/C8H8N4/c9-8-7(5-11-12-8)6-1-3-10-4-2-6/h1-5H,(H3,9,11,12)

Upstream product

• 92333-25-0 pyridin-4-ylacetonitrile hydrochloride 
• 103851-89-4 3-(dimethylamino)-2-(4-pyridyl)prop-2-enenitrile 
• 69512-60-3 cyano-pyridin-4-yl-acetic acid ethyl ester 
• 13121-99-8 pyridin-4-ylacetonitrile 
• 10445-91-7 4-(Chloromethyl)pyridine 
• 493038-83-8 (Z)-3-(dimethylamino)-2-(4-pyridyl)prop-2-enenitrile 

Downstream Products

• 216661-58-4 3-(pyridin-4-yl)-6-(4-methoxyphenyl)-pyrazolo(1,5-A)pyrimidine 
• 1062368-41-5 6-{4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-3-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine 
• 515880-87-2 6-(4-hydroxyphenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine 
• 597544-21-3 4-(2-(4-(3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine 
• 866405-64-3 dorsomorphin 

Relevant articles and documents

HERBICIDAL COMPOUNDS

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.